Australia's Prescient Therapeutics rises on positive result from drug expansion study

Prescient Therapeutics

16/03/2023 03:21

** Shares of Prescient Therapeutics Ltd  PTX.AX  rise as
much as 8.3% to A$0.130
    ** Clinical-stage oncology co says continued promising
results in PTX-100's Phase 1b expansion cohort study with
positive responses in patients with relapsed and refractory
Peripheral T-cell lymphomas (PTCL)
    ** PTX-100 is a first-in-class compound with the ability to
block an important cancer growth enzyme, co says
    ** Further adds plans to increase number of patients to
create robust regulatory package for U.S. FDA meeting
    ** More than 3.2 mln shares change hands, vs the 30-day
average volume of 1.1 mln shares
    ** Stock has fallen 11.1% this year, as of last close

 (Reporting By Udbhav Krishna P in Bengaluru)
 ((UdbhavKrishna.P@Thomsonreuters.com))